**DIRECTIONS TO USE THIS TEMPLATE:**

* **Do not adjust the bottom margin or use the footer**; it has been reserved for use by the IRB.
* Follow the italicized guidelines in red print and complete as applicable for your project. Words in black print or Green are generally expected be used without modification; those in blue print are examples/optional. Please **delete the template guidelines and unwanted text** after the document is completed.
* The consent form should include all the section headings indicated in the template unless otherwise indicated.
* The headings of this consent form are generally phrased as questions from the participant; the content of each section is generally written as the response from the study team. The form should provide information that a reasonable person would want to have in order to make an informed decision about whether to participate or not.
* The consent form may **not** contain exculpatory language through which the participant is made to waive or appear to waive any of the participant’s legal rights, or releases or appears to release the investigator or the Institution from liability for negligence. Phrases such as “I understand…” or “You understand…” are not appropriate as they can be interpreted as suggestive and can constitute coercive influence over a participant.
* The consent form should be written at an appropriate grade level for the group of participants, usually no higher than the 8th grade level based on an electronic grade level scoring system, which is available with most word processing systems. The IRB may consider higher reading grade levels based on the populations targeted in the study.
* The consent form must be organized and presented in a way that does not merely provide lists of isolated facts, but rather facilitates the understanding of the prospective participant or LAR of the reasons why one might or might not want to participate.
* Informed consent is a process, not just a form. The written presentation of information can be used as a teaching tool to document the basis for consent and for the participants' future reference. Obtaining informed consent is a fundamental mechanism to ensure respect for persons through provision of thoughtful consent for a voluntary act. The consent document should be revised when deficiencies are noted or when additional information will improve the consent process.
* The procedures used in obtaining informed consent should be designed to educate potential participants in language that they can understand. If a Principal Investigator proposes to use a participant population that does not speak or read English, a copy of the translated document, as well as the English version, needs to be forwarded to the IRB for approval.
* For projects involving VA employees as participants, Principal Investigators need to carefully review the template and not include any elements that may not pertain to these types of studies, such as statements involving usual care, alternate treatments, or current relationships with participant’s health care providers.
* **Collection of full name and last 4 of SSN are needed for studies where the consent form will be filed in the medical record**

**WRITING TIPS THAT MEETS READABILITY REQUIREMENTS:**

* Use as few words with three or more syllables as possible
* Break all compound sentences into separate short sentences.
* Use simple, declarative statements where possible.
* Change all passive voice sentences to active voice.
* Proofread for spelling, typographical, and grammatical errors.
* Avoid imbedding list in phrases, instead breakdown into bullets or into a numbered list
* Use tables to present information such as visits, procedures and compensation
* Avoid using technical terms. If you must use them, explain what they mean in lay language.
* Restrict descriptions of procedures to those things the participants will actually experience.

**WHAT IS THE STUDY ABOUT AND WHY ARE WE DOING IT?**

We are asking you to choose whether or not to volunteer for a research study being funded by [the Department of Veterans Affairs; is unfunded; or is funded by add additional funding sources if necessary].about \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ {insert concise, general description of study}. This initial information is to give you key information to help you decide whether to participate. We have included detailed information after this information. Ask the research team questions. Taking part in this study is completely voluntary.

**what is the STUDY ABOUT AND HOW LONG WILL IT LAST?**

***Briefly*** *describe the purpose of the study and the procedures to be followed in lay terms. For detailed descriptions, use the Detailed Consent.*

By doing this study, we hope to learn \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_. Your participation in this research will last about {*state in hours, days, months, years*}.

*If testing Food and Drug Administration (FDA)-regulated products for safety or effectiveness include the following:* The purpose of this research is to gather information on the safety and effectiveness of \_\_\_\_\_\_\_\_\_\_\_\_ *{state name of drug, device, etc.}. Indicate if the drug, device, or biologic is FDA-approved and whether it is being used in the study for an alternate use or consistent with labeling indications.*

**what are key reasons you might choose to volunteer for this study?**

State the most important reason(s) {i.e. potential benefit(s)} a person may want to volunteer to participate in this study? For a complete description of benefits, refer to the Detailed Consent.

**what are key reasons you might choose not to volunteer for this study?**

State the most important reason(s)/risk(s) why a participant may NOT want to volunteer for this study considering the participant’s perspective. For a complete description of risks, refer to the Detailed Consent and/or Appendix.

If *alternative treatments/procedures are key to the participant’s choice, discuss those that might be advantageous to the subject or indicate if no known alternative exists.* For a complete description of alternate treatment/procedures, refer to the Detailed Consent.

**DO YOU HAVE TO TAKE PART IN THE STUDY?**

If you decide to take part in the study, it should be because you really want to volunteer. You will not lose any services, benefits or rights you would normally have if you choose not to volunteer.

**what if you have questions, suggestions or concerns?**

The person in charge of the study is \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ *{Principal Investigator, PI}* of the [insert name of VA] If you have questions, suggestions, or concerns regarding this study or you want to withdraw from the study his/her contact information is: {*PI contact information}*.

 **RESEARCH DETAILS**

**WHAT IS THE PURPOSE OF THIS STUDY?**

*In this section include why the research is being done. Ensure scientific language is explained in lay terms. Include if a drug or device used in the project has or has not been approved by the Food and Drug Administration for the specific use being evaluated in the project.*

With this research we hope to learn….

**HOW LONG WILL I BE IN THE STUDY?**

*Explain in lay language how many subjects will participate in this study for this site and the duration of the individual’s participation in the study. Also state the length of time the study will last overall.*

This research study is expected to take approximately {X years, months, days}. Your individual participation in the project will take {X days, weeks, months, years}.

**WHAT WILL HAPPEN IF I TAKE PART IN THE STUDY?**

*Describe the procedures that will take place during the study. Clearly identify those that are experimental. Use lay terms and provide details.*

*Use a bullet outline or small paragraphs and subparagraphs to clearly outline what will happen in a step-by-step sequence.*

**WHAT IS EXPECTED IF I TAKE PART IN THIS STUDY?**

*Provide a detailed description and explain the participant’s time involved for each procedure or interaction, considering the following requirements:*

* *Provide a chronological explanation of the procedures that will be performed, distinguishing which procedures are experimental (being done solely for the purposes of the research, to include the use of investigational drugs and devices) vs. which are considered standard of care (for diagnostic or treatment purposes). Use a bullet outline or small paragraphs and subparagraphs to clearly outline what will happen in a step-by-step sequence.*
* *Use lay terms to describe medical terminologies (see* [*glossary*](https://www.portland.va.gov/research/documents/hrpp/glossary-of-lay-terms.pdf)*), e.g.:*
	+ Catheter: a flexible tube for withdrawing or introducing fluids, put under the skin or into a vein using a needle; the tube may be left in for long periods after the needle used to insert it is removed.
* *Clearly indicate who is overseeing a procedure, the study team or the participant’s health care provider as part of usual care, so it is clear to the participant who is responsible for the following:*
	+ *Risks and discomforts are explained in the next section*
	+ *Providing the treatment or service*
	+ *Monitoring the treatment or service as applicable*
	+ *Defining whether adverse events result from usual care or research*
	+ *Alerting the participant if there is a problem with the treatment or service*
	+ *Documenting the participant’s clinical course while receiving the treatment or service*
* *For research involving randomization of participants into different study arms, specify the randomization process, explaining it in lay language, e.g. “*by chance.”
* *Include all the different people by study role with whom the participant will interact.*
* *Indicate when and where the study procedure(s) will be done.*
* *Specify how often the procedures will be performed and how long each will take.*
* *Indicate type and frequency of safety monitoring during and after the study.*
* *If applicable, include information regarding pregnancy testing for women of childbearing potential and indicate the frequency of the testing. If required for the study, birth control measures may be listed here.*
* *If the study includes surveys or questionnaires, include a statement that the participant is free to skip any questions that he/she would prefer not to answer.*
* *Include a full explanation of all responsibilities and expectations of the participant. You can include applicable points from the list below and/or add your own per study requirements:*
	+ Take the study drug as instructed. *(If device, explain what is required for study compliance).*
	+ Keep your study appointments. If you miss an appointment, please contact the investigator or research staff to reschedule as soon as you know you will miss the appointment.
	+ Tell the investigator or research staff if you believe you might be pregnant or might have gotten your partner pregnant.
	+ Keep the study drug in a safe place for your use only and away from children
	+ Fill out your diaries as instructed.
	+ Complete your questionnaires as instructed.
	+ Ask questions as you think of them.
	+ While participating in this research study, do not take part in any other research project without approval from the investigators. This is to protect you from possible injury from things such as extra blood drawing, extra X-rays, or potential drug interactions. Taking part in other research studies without first discussing it with the investigators of this study may invalidate the results of this study, as well as that of the other studies.
* *If applicable, state if the participant will receive a general report of the aggregate results or any results specific to the participant (that are distinguished from significant new findings in Section 14 below).*

**WHAT POSSIBLE RISKS OR DISCOMFORTS MIGHT I HAVE IF I TAKE PART IN THIS STUDY?**

*Suggested wording that can be modified based on the type of research you are proposing to conduct:*  Any procedure has possible risks and discomforts. The procedures in this study may cause all, some, or none of the risks or side effects listed. Rare, unknown, or unexpected risks also may occur.

* *Identify each intervention/procedure with a subheading and then describe any reasonable foreseeable risks, discomforts, and inconveniences, and how these will be managed. Include the probability of the risks, especially those that are likely and those that are rare but serious.*
* *In addition to physical/physiological risks/discomforts, describe any psychological, social, legal, or financial risks that might result from participating in the study, to include risks inherent in genetic analysis and tissue banking if applicable.*
* *If there are any significant risks to participation that might cause the researcher to withdraw the participant or terminate the study, these should be described.*
* *Give measures which will be employed to minimize the described risks, discomforts, and inconveniences.*

*For studies involving possible reproductive risks, please include a section that includes the following:*

* *State any known risks in pregnancy, either to mother or child.*
* *State that there may be unforeseeable (unanticipated) risks to the participant (or to the embryo or fetus) if the participant is pregnant or becomes pregnant during the study.*
* *List the acceptable methods of birth control for this research study.*
* *Describe what action will occur in the event of pregnancy, e.g., follow-up of pregnancy outcome, immediate withdrawal from the study, etc.*
* *Describe if there is any effect on sperm count or the motility of sperm or other reproductive risks associated with fathering a child.*
* *Describe if there are any known risks to gametes.*

*Describe the known risks associated with the study drug, device, procedure, intervention, etc. Consider using the below headings, as applicable. There is no standard definition for the below categories, but could be defined as: Common, occurring greater than 20% and up to 100%; Occasional, occurring 4% to 20%; rare, less than 3%.*

1. **Common risks** *<state if some may be serious, e.g.* **(some may be serious)***>***:**

In 100 people receiving *<type or name of study drug/device/procedure>*, more than 20 and up to 100 may have:

*• <insert bullet point list of risks, and how serious each one is>*

1. **Occasional** *<state if some may be serious, e.g.* **(some may be serious)***>***:**

In 100 people receiving *<type or name of study drug/device/procedure>*, from 4 to 20 may have*:*

*• <insert bullet point list of risks, and how serious each one is>*

1. **Rare** *<state if some may be serious, e.g.* **(some may be serious)***>***:**

In 100 people receiving *<type or name of drug/device/procedure>*, 3 or fewer may have*:*

*• <insert bullet point list of risks, and how serious each one is>*

*Include the following information verbatim:*

There is always a chance that any procedure can harm you. The procedures in this study are no different. In addition to the risks described above, you may experience a previously unknown risk or side effect.

Risks of the usual care you receive are not risks of this study. Those risks are not included in this consent form. You should talk with your health care providers if you have any questions about the risks of usual care.

*For common procedures (e.g. blood drawing, MRI), or if women of child bearing potential may be included in the study, use the following generally applicable statements as appropriate:*

* (1) Blood drawing

There may be some discomfort, bruising, or bleeding at the site where the blood is drawn. Rarely, fainting occurs because of drawing blood.

* (2) MRI

Some people experience a 'closed-in' feeling due to the relatively restricted space within the MRI machine. You may not be able to have the MRI procedure if you have certain metal, surgical clips, or implants, including a brain aneurysm clip or a pacemaker, in your body, because during the MRI procedure metal can heat up and move, or clips and implants stop working. Dental fillings are not a problem. If there is any question about whether or not there is metal in your body, you may be requested to have an X-ray to determine this; the X-ray will become part of your medical record. If you are pregnant, you should delay having an MR scan. You will need to remove all jewelry or clothing with metal before having the MRI. All of these precautions will be reviewed with you immediately before you have the MRI.

* (3) Questionnaires

Some people become uncomfortable at being asked questions about \_\_\_\_\_\_\_\_; if, for any reason, you wish not to answer specific questions or you wish to terminate the session, you will be able to do so.

* (4) Photographs, audiotaping, or videotaping

*Choose either:  <*There will be no photographs, audio tapes, or video tapes made of you as part of this study.*> OR <* The study team has explained that by signing this Informed Consent Document, you voluntarily and without separate compensation authorize pictures and/or voice recording(s) to be made of you by the XXX while you are participating in this study.  You also authorize disclosure of the picture and/or voice recording to *<insert name and business address of every entity that xxx will release copies of the recording to>.* The said picture, video, and/or voice recording is intended for the following purposes: *<insert description of the purpose for taking the pictures>.*

The study team has also explained that you will not receive any royalty, fee or other compensation for such use. If you refuse to grant consent, there will be no effect on any VA benefits to which you may be entitled. You may at any time exercise the right to cease being filmed, photographed or recorded, and may rescind your consent for up to a reasonable time before the picture, video or voice recording is used.

*If the recording is an optional part of the study, such that a participant could refuse to be recorded but still be an active participant in the study, also insert the following:*

Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_   Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

* *(5) Inclusion of Women of Childbearing Potential*

*The policy of the FDA, the NIH, and other Federal agencies regarding the research participation of women with childbearing potential has changed substantially in the past few years. Studies are now mandated to include such women unless there is a clear and justifiable reason to exclude them. Studies involving investigational drugs should typically include the following statement in the RISKS section of the ICF:*

The safe use of *<drug name>* in pregnant women and nursing mothers has not been established. Consequently, there may be risks to you (or to your embryo or fetus) if you are or may become pregnant that are unknown. Women of childbearing potential enrolling in this study must (i) have been using a birth control measure (an intrauterine device (IUD), birth control pills, a condom, diaphragm, or abstinence) for the previous three months, (ii) must have a negative pregnancy test, and (iii) must agree to continue to use a birth control measure for the duration of the study. If, while participating in the study, you suspect you have become pregnant, please contact the study physician immediately. Women are considered to be of childbearing potential unless they have been surgically sterilized (for example tubal ligation or hysterectomy) or are post-menopausal, that is, no menstrual period for more than 6 months. Nursing mothers may not participate in this study.

*For studies involving drugs that are known or suspected mutagens or teratogens (i.e., could cause birth defects), the potential benefit to the female participant of participating in the study must be weighed against the potential damage to a fetus.*

**WHAT ARE THE POSSIBLE BENEFITS OF THIS STUDY?**

*This section must describe any potential direct benefits to the participant or to others which may reasonably be expected from the study. The description of benefits to the participant should be clear and not overstated in order to avoid the appearance of undue influence or coercion. If no direct benefit is anticipated, this should be stated. If study results will be given to the participant, this should be stated. List direct benefits, such as receiving an FDA-approved medication to treat a condition that would not otherwise be treated or being enrolled in one of two (both generally believed to be effective) counseling modalities not normally offered by the VA. Rule of thumb: if the VA offers the participant population any other effective treatment for the study condition, and/or if the study treatment is not FDA-approved to treat the study condition, and/or if there is a chance any participant will receive an ineffective placebo, enrolling in the study does not offer a direct benefit.*

***DO NOT*** *include any payment to be offered to participants for taking part. Not acceptable are statements that cite potential indirect benefits, such as receiving more intensive medical care, getting access to a potentially effective (investigational) medication, or being paid/ reimbursed travel costs/meals to participate.*

*Some examples on how to complete this section follow:*

We do not know if you will get any benefits from taking part in this research study. However, possible benefits may include *<list benefits>.*

 ***OR***

There are no direct/personal benefits to you from your taking part in this research study. However, the information we get from this study might help others with your conditions.

**WHAT OTHER CHOICES DO I HAVE IF I DO NOT WANT TO JOIN THIS STUDY?**

*If there are no alternative procedures/treatments to participating in this study, such as if the only alternative is not to participate in this study, this section should not be included in the informed consent form.*

*Describe alternative procedures or courses of treatment to participating in this study. To enable a rational choice about participating in the research study, individuals should be aware of the full range of options available to them, including palliative or comfort care (if applicable).*

*Example:* You may choose not to participate in this study. If this is your decision, there are other choices such as … *<list alternatives, e.g. surgical treatment, lifestyle changes, etc.>.*

*If standard therapy is part of the research study, the participant must be told he or she can receive it outside of participation in the study, and state:*

You may discuss these options with your doctor.

**HOW WILL MY PRIVATE INFORMATION BE PROTECTED?**

*Describe the procedures used to maintain the confidentiality of the records and data pertaining to the participant, how the participant’s privacy will be protected, and who may inspect the records.*

*For all studies that involve the collection of identifiable private information or identifiable specimens, include a statement on whether specimens if subsequently de-identified will be used for future research or not*

*If applicable, please provide a description of the Certificate of Confidentiality and any voluntary disclosure plan, or the potential for disclosures required by law, e.g., elder abuse, child abuse, study participants posing a danger to themselves or others, etc.)*

*Example:* We have obtained a Certificate of Confidentiality from the Federal Government. This helps protect your privacy by allowing us to refuse to release your name or other information outside of the research study, even by a court order. The Certificate of Confidentiality will not be used to prevent disclosures to local authorities of child abuse or neglect, or harm to self or others. The Certificate does not prevent you or a member of your family from releasing data about yourself or your involvement in this study.

*If the study procedures have any implication on the patient’s care, the study team is required to put any details about the subject’s participation that are relevant to their care providers in the patient’s medical record. Therefore, for all studies that involve a medical intervention, you must include the following statement:*

*We will include information about your study participation in your medical record.*

*If the research is a clinical trial subject to FDA regulation, the following statement must be included:*

A description of this clinical trial will be available on <http://www.ClinicalTrials.gov> as required by U.S. Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.

**Health Information Portability and Accountability Act (HIPAA)**

**Include the following language in GREEN verbatim: {IF IMPARIED DECISION MAKING INDIVIDUALS – REMOVE THIS WORDING AND SUBMIT A SEPARATE 10-4093 *HIPAA AUTHORIZATION FORM}***

There are rules to protect your private health information. Federal and state laws and the federal medical law, known as the HIPAA Privacy Rule, also protect your privacy. By signing this form, you provide your permission called your ‘authorization,’ for the use and disclosure of information protected by the HIPAA Privacy Rule.

The research team working on the study will collect information about you. This includes things learned from the procedures described in this consent form. They may also collect other information including your name, address, date of birth, and information from your medical records such as **{MODIFY AS APPROPRIATE}** medical history, allergies, lab results, HIV status, drug, alcohol or STD treatment, genetic test results or mental health treatment.

The research team may also need to disclose your health information and the information it collects to others as part of the study progress. Others may include the **{MODIFY AS APPROPRIATE}**VA Cooperative Studies Program (CSPCC); CSP Clinical Research Pharmacy Coordinating Center (CSPCRPCC); CSP Site Monitoring; Auditing and Review Team (SMART); CSPCC’s Human Research Committee (HRC); **{ADD ENTITIES SUCH AS SPONSOR, CONTRACTORS, AFFILIATES AS APPROPRIATE}**; Institutional Review Board, Food and Drug Administration, Office (FDA), Office of Human Research Protections (OHRP), the VA Office of Research Oversight (ORO), and the Government Accountability (GAO).

Your health information disclosed pursuant to this authorization may no longer be protected by Federal laws or regulations and may be subject to re-disclosure by the recipient.

You can revoke this authorization, in writing, at any time. To revoke your authorization, you must write to the Release of Information Office at this facility or you can ask a member of the research team to give you a form to revoke the authorization. Your request will be valid when the Release of Information Office receives it. If you revoke this authorization, you will not be able to continue to participate in the study. This will not affect your rights as a VHA patient to treatment or benefit outside of the study.

If you revoke this authorization, **(insert name of Site Investigator)** and his or her research team can continue to use information about you that was collected before receipt of the revocation. The research team will not collect information about you after you revoke the authorization.

Treatment, payment or enrollment/eligibility for benefits cannot be conditioned on you signing this authorization. This authorization will expire at the end of the research study unless revoked prior to that time.

**WHAT ARE THE COST TO ME IF I TAKE PART IN THIS STUDY?**

*Explain in lay language what the cost to participate will be, if any. Ensure there is a statement that veteran-participants will not be required to pay for care received as a participant in a VA research study such as the statement below:*

You will not be charged for any treatments or procedures that are part of this study. If you usually pay co-payments for VA care and medications, you will still pay these co-payments for VA care and medications that are not part of this study.

*If payment is being offered for participation in the study, a separate subheading must be included with the following information. (If there is no payment being offered for participation, this should be so stated.)*

* *State whether the payment will be financial or something else such as a gift card, etc.*
* *If the payment is financial, describe the amount the participants will be paid, when payment is scheduled, how the payment will be disbursed, and the pro-rated amount the participant will receive should the participant decide to withdraw from the study or is withdrawn by the investigator.*
* *If the participant is reimbursed for certain expenses like transportation and parking, list the reimbursement rates.*
* *State who will be disbursing the payments. Due to limitations in the Financial Management System, payments made to subjects through Austin Financial Services Center generate Internal Revenue Service Form 1099 regardless of amount. This information and the fact that the SSN of the subject will be used for this purpose must be included in the informed consent form.*

*Note: VA policy prohibits paying human subjects to participate in research when the research is integrated with a patient’s medical care and when it makes no special demands on the patient beyond those of usual medical care. Any payment offered should be commensurate with the time and inconvenience of the participant incurred by the participant that they otherwise would not have incurred, as well as to cover travel expenses.*

**WHAT WILL HAPPEN IF I AM INJURED BECAUSE OF MY BEING IN THE STUDY?**

*Describe an explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs.*

*Include a statement that VA will provide treatment for research related injury in accordance with applicable federal regulations (38 CFR 17.85 ). The IRB may waive inclusion of this statement in the informed consent form for minimal risk studies if it determines and documents that it not does alter the rights and welfare of the subjects*

*Provide an explanation of whether any compensation is available should an injury occur.*

*In addition, provide an explanation as to whether any medical treatments are available if injury occurs, and if so, what they consist of, or where further information may be obtained. Include specific information about whom the participant should contact in case of a research-related injury. This should include name(s), telephone number(s), and when the person(s) listed may be contacted.*

*Example:* If you should have a medical concern or get hurt or sick as a result of taking part in this study, call: *(List local site contacts)*

DURING THE DAY:

Dr./Mr./Ms. at and

AFTER HOURS:

Dr. /Mr./Ms. \_\_\_\_\_ at \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.

Emergency and ongoing medical treatment will be provided as needed.

**DO I HAVE TO TAKE PART IN THE STUDY?**

*State that participation is voluntary. Indicate that refusal to take part in the study will involve no penalty or loss of benefits to which the participant is otherwise entitled.*

*If the participant is a VA employee or student, indicate that refusal to take part in the study will in no way influence their employment, ratings, subsequent recommendations, or academic progress as applicable. Also indicate that the participant may discontinue taking part at any time without any penalty or loss of benefits. If applicable, state that the participant may withdraw and still receive the same standard of care that he or she would otherwise have received.*

*Explain any possible consequences of a participant’s decision to withdraw from the research. Describe any adverse effects on the participant’s health or welfare, or any extra follow-up that may be requested if the participant decides to withdraw from the study.* ***Explain the procedures for an orderly termination of participation. Such an explanation may be omitted if there are no adverse consequences to withdrawal.***

*Indicate that for data already collected prior to the participant’s withdrawal, that the investigator may continue to review the data already collected for the study but cannot collect further information, except from public records, such as survival data. Also indicate that specimens already used cannot be withdrawn, if applicable.*

**RIGHT OF INVESTIGATOR TO TERMINATE MY PARTICIPATION (Include if applicable)**

*Describe foreseeable circumstances under which the participant’s participation might be terminated by the investigator without regard to the participant’s consent. This section may be omitted if there is only a one-time intervention or there are no circumstances in which the investigator would terminate the participation of an individual participant.*

*If the investigator might terminate participation of a participant, possible reasons should be listed and the procedures for an orderly termination of participation described. Include a description of any adverse effects on the participant’s health or welfare that may result, or any additional follow-up that may be requested after the participant is withdrawn from the active portion of the study.*

**WHO DO I CONTACT ABOUT THIS STUDY IF I HAVE QUESTIONS?**

*Explain whom participants should contact with any questions, complaints, and concerns about the research or related matters. Contact information for the investigator should be included for questions about the research.* ***At least one of the contacts must be someone other than the investigator or other study personnel such as the local Patient Advocate****. Make sure you inform all persons listed that they are points of contact for participants and ensure they are knowledgeable concerning the study. Document the contact as part of your research records.*

***Include the following statement verbatim:***  If you have questions about your rights as a study participant, or you want to make sure this is a valid VA study, you may contact the Institutional Review Board (IRB). This is the Board that is responsible for overseeing the safety of human participants in this study. You may call the [list your site contact information here] if you have questions, complaints or concerns about the study or if you would like to obtain information or offer input.

**WILL I BE TOLD NEW INFORMATION ABOUT THIS STUDY?**

*State that new findings developed during the course of the research that may affect the participant’s willingness to continue participation will be provided to the participant. This section may be omitted if new information could not reasonably be used to alter participation (e.g., one-time interventions that are no greater than minimal risk).*

*Included a statement whether clinically relevant research results will be disclosed to subjects and if so under what conditions*

WHO COULD PROFIT FROM THE STUDY RESULTS? (If applicable)

Describe any payments that are being made to investigators that could be construed as a potential conflict of interest. If a conflict of interest cannot be eliminated after the review by the IRB, the IRB may require that this section be included.

Include a statement whether specimens may be used for commercial profit and if subjects will share in the profit.

If a possible commercial product will be developed as part of this research, explain that the participant will not profit from any products or tests that might result based on research with their specimens

DOES THIS STUDY INVOLVE GENETIC RESEARCH? HOW WILL MY GENETIC INFORMATION BE PROTECTED? (If applicable)

*Include a statement whether the research might include whole genome sequencing.*

Describe in this section possible limits to individual confidentiality based on the technologies involved in the researchClarify when and under what conditions research results of genetic testing will be conveyed to the participant, the participant’s family, or the participant’s physician.

Consdider GINA language:

*Include the following statement verbatim, if applicable:*

Federal laws and policies provide you with protection from discrimination by health insurance companies, group health plans, and most employers based on your genetic information.  A federal law called the Genetic Information Nondiscrimination Act (GINA) generally will protect you in the following ways:

* Health insurance companies and group health plans may not request your genetic information obtained from this study.
* Health insurance companies and group health plans may not use your genetic information obtained from this study when making decisions regarding your eligibility or premiums.
* Employers with 15 or more employees may not use your genetic information obtained from this study when making a decision to hire, promote, or fire you or when setting the terms of your employment.

Be aware that this Federal law does not protect you against genetic discrimination by companies that sell life insurance, disability insurance, or long-term care insurance. It also does not prohibit discrimination on the basis of already known genetic disease.

FUTURE USE OF DATA AND RE-CONTACT

If any of the participant’s data are going to be retained after the study for future research, the following information must be provided to the participant:

* Where will the data be stored
* Who will have access to the data

If the subject is going to be re-contacted in the future about participating in future research, this must be specified. Describe the circumstances under which the participant would be re-contacted whether within the VA or outside the VA.

**IF DATA BANKING OR TISSUE BANKING IS AN OPTIONAL COMPONENT OF THE STUDY- ALSO SUBMIT A SEPARATE 10-0493 *HIPAA AUTHORIZATION FORM* TO ADDRESS OPTIONAL COMPONENT.**

TISSUE BANKING (Include if Applicable)

*If you are planning to store blood, tissues, or specimens of any kind for future research, tissue banking guidelines must be addressed.*

*A separate consent form will also be required for the collection of DNA for the sole purpose of adding the specimen to the CSP VA Genomic Medicine Program Biorepository or if a specimen will also be used for the Million Veteran Program (MVP).*

*Describe where the specimens will be stored, who will have access to them, and how long they will be retained.*

*Clarify when and under what conditions research results will be**conveyed to the participant, the participant’s family, or the participant’s physician.*

*Explain if the participant will be re-contacted after the original project is complete. In addition to the above, specify why the tissue is being banked and the potential future uses.* ***If applicable,*** *you may want to give participants a choice of whether tissue can be banked.* ***An example*** *of providing the participants a choice is provided below:*

Please read each sentence below, think about your choice, and mark “**YES**” or “**NO**”. **No matter what you decide to do, your decision will not affect your medical care or your participation in the study already described.**

May the <<site>> or its research partners in this study retain your <<describe specimen (e.g., tissue, blood, urine, body fluid)>> specimen(s) after the end of the study for use in future research?

**[ ]  YES My specimen(s) may be saved for future research as follows:**

**Check all restrictions that apply:**

**[ ]  None. My specimen may be used for any future research**

**[ ]  Only research by the current principal investigator**

**[ ]  Only research that does not involve genetic testing**

**[ ]  Only research that involves the disease or condition to which this study pertains**

 **OR**

**[ ]  None of the above. The specimen may only be used under the following conditions:**

 **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**[ ]  NO My specimen(s) must be destroyed at the end of this research study.**

If yes, may the <<site>> or its research partners in this study keep your name and other identifying information with your specimen(s)?

**[ ]  YES My personal** **identifiers and medical information can be kept with my specimen(s). All information will be kept secure and confidential.**

**[ ]  NO My name and identifiers must be removed from my specimen(s). My specimen(s) cannot be linked back to me.**

If you gave consent for the specimen(s) to be used in future research by the <<site>> or its research partners, an Institutional Review Board (IRB) will review and approve each new study. The IRB may require that you be contacted for your consent prior to the use of the specimen(s) in a new study if it decides such consent is required for your protection.

You have the right to withdraw your consent in the future and have your unused specimen destroyed. You need to notify the investigator of your decision. If you decide to remove identifiers from your specimen(s), you will not be able to withdraw your specimen later because it cannot be linked back to you.

**AGREEMENT TO PARTICIPATE IN THE RESEARCH STUDY**

*The following language must be included verbatim unless otherwise indicated:*

Dr./Mr./Ms\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ *(or you can indicate a study role that has been delegated by the PI to obtain informed consent)* has explained the research study to you. You have been told of the risks or discomforts and possible benefits of the study. You have been told of other choices of treatment available to you. You have been given the chance to ask questions and obtain answers.

By signing this document below, you voluntarily consent to participate in this study INSERT IF COMBINED WITH AUTHORIZATION VERBATIM “and authorize the use and disclosure of your health information for this study”. You also confirm that you have read this consent, or it has been read to you. You will receive a copy of this consent after you sign it. *(Include if applicable:* A copy of this signed consent will also be put in your medical record.*)*

|  |
| --- |
| **I agree to participate in this research study as has been explained in this document.** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Participant’s Name | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Participant’s Signature | \_\_\_\_\_\_\_\_\_\_\_Date |

*Note: The use of a witness signature is optional. If the IRB determines that a witness signature is required, an additional line for the witness signature must be added above the name of the person obtaining consent. Usually, a witness is solely witnessing the signature of the participant but the IRB may determine that the witness must witness the entire consent process. A note should be added below the signature of the witness indicating what the role of the witness is.*

*IMPORTANT: The below signature block for Legally Authorized Representatives (LAR) is only used for populations unable to provide informed consent. Only use the LAR signature block in place of the participant’s signature block if it has been explained in the new study application (subject to approval by the IRB) that these types of populations are going to be used in the study). Delete this if you do not plan to enroll participants using an LAR.*

|  |
| --- |
| **The participant is unable to give informed consent. I, as the legally authorized representative of the participant, give consent for their participation in this study.** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Name of Legally Authorized Representative | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Signature of Legally Authorized Representative | \_\_\_\_\_\_\_\_\_\_Date |
| **Indicate below your authority to act as the participant’s legally authorized representative:**[ ]  Spouse[ ]  Parent[ ]  Adult Child (18 years of age or over) for his or her parent [ ]  Adult Sibling (18 years of age or over)[ ]  Grandparent[ ]  Adult Grandchild[ ]  Guardian appointed to make medical decisions for individuals who are incapacitated[ ]  Other per local or state law Specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |

***Additional Notes to Study Team Members:*** *Informed consent is a process, not just a form. The written presentation of information can be used as a teaching tool to document the basis for consent and for the participants' future reference. Obtaining informed consent is a fundamental mechanism to ensure respect for persons through provision of thoughtful consent for a voluntary act. The consent document should be revised when deficiencies are noted or when additional information will improve the consent process.*

*The procedures used in obtaining informed consent should be designed to educate potential participants in language that they can understand. If an investigator proposes to use a participant population that does not speak or read English, a copy of the translated document, as well as the English version, needs to be forwarded to the IRB for approval.*

*For projects involving VA employees as participants investigators need to carefully review the template and not include any elements that may not pertain to these types of studies, such as statements involving usual care, alternate treatments, or current relationships with participant’s health care providers.*